2 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 32026-09-29NCT06881784
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmActive, not recruitingPhase 22026-07-14NCT02864992